BRPI0914305B8 - compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos - Google Patents

compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos

Info

Publication number
BRPI0914305B8
BRPI0914305B8 BRPI0914305A BRPI0914305A BRPI0914305B8 BR PI0914305 B8 BRPI0914305 B8 BR PI0914305B8 BR PI0914305 A BRPI0914305 A BR PI0914305A BR PI0914305 A BRPI0914305 A BR PI0914305A BR PI0914305 B8 BRPI0914305 B8 BR PI0914305B8
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitor
composition
substituted carboxamide
pyridazine
Prior art date
Application number
BRPI0914305A
Other languages
English (en)
Inventor
Liang Congxin
Li Zhigang
Original Assignee
Xcovery Holding Co Llc
Xcovery Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xcovery Holding Co Llc, Xcovery Holdings Inc filed Critical Xcovery Holding Co Llc
Publication of BRPI0914305A2 publication Critical patent/BRPI0914305A2/pt
Publication of BRPI0914305B1 publication Critical patent/BRPI0914305B1/pt
Publication of BRPI0914305B8 publication Critical patent/BRPI0914305B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

compostos de piridazina carboxamida substituída como compostos inibidores da quinase os derivados de piridazina têm propriedades de droga inesperadas como inibidores da proteína quinase e são úteis no tratamento de distúrbios relacionados a atividades anormais da proteína quinase, tais como câncer.
BRPI0914305A 2008-06-19 2009-06-18 compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos BRPI0914305B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13250508P 2008-06-19 2008-06-19
US61/132,505 2008-06-19
PCT/US2009/003654 WO2009154769A1 (en) 2008-06-19 2009-06-18 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds

Publications (3)

Publication Number Publication Date
BRPI0914305A2 BRPI0914305A2 (pt) 2015-08-11
BRPI0914305B1 BRPI0914305B1 (pt) 2021-05-11
BRPI0914305B8 true BRPI0914305B8 (pt) 2021-05-25

Family

ID=41434356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914305A BRPI0914305B8 (pt) 2008-06-19 2009-06-18 compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos

Country Status (15)

Country Link
US (3) US8697866B2 (pt)
EP (2) EP2303018B1 (pt)
JP (1) JP5670325B2 (pt)
KR (1) KR101691640B1 (pt)
CN (1) CN102098917B (pt)
AU (1) AU2009260810B2 (pt)
BR (1) BRPI0914305B8 (pt)
CA (1) CA2728408C (pt)
ES (2) ES2670665T3 (pt)
IL (1) IL210099A (pt)
MX (1) MX2010014171A (pt)
NZ (1) NZ590542A (pt)
PL (1) PL2303018T3 (pt)
RU (1) RU2526618C2 (pt)
WO (1) WO2009154769A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154769A1 (en) * 2008-06-19 2009-12-23 Xcovery, Inc. Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
CN102812018A (zh) * 2010-03-23 2012-12-05 巴斯夫欧洲公司 用于防治无脊椎动物害虫的哒嗪化合物
AU2011311814B2 (en) 2010-10-08 2016-12-22 Xcovery Holdings, Inc. Substituted pyridazine carboxamide compounds
BR112013009260A2 (pt) 2010-10-08 2016-07-26 Xcovery Holding Co Llc compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
US9328106B2 (en) 2012-09-26 2016-05-03 Genentech, Inc. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN102952091A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种4-氨基异恶唑盐酸盐的合成方法
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
EP3826999A1 (en) * 2018-07-24 2021-06-02 Epizyme Inc Pyridin-2-one compounds useful as smarca2 antagonists
US20220055992A1 (en) * 2018-12-21 2022-02-24 Saltigo Gmbh Process for preparing 2-alkoxy-4-amino-5-methyl-pyridines and/or 2-alkoxy-4-alkylamino-5-methyl-pyridines
CN112457268A (zh) * 2020-12-11 2021-03-09 平江县吉成科技有限责任公司 一种温和的4-氨基异恶唑盐酸盐的合成方法
CN116082110B (zh) * 2023-01-09 2024-04-12 北京肿瘤医院(北京大学肿瘤医院) 一种11c标记靶向间变性淋巴瘤激酶alk突变分子探针及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
PL205708B1 (pl) * 2001-09-21 2010-05-31 Lilly Co Eli Związki agonistyczne receptora muskarynowego, kompozycja zawierająca te związki i zastosowanie tych związków
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
AP2114A (en) 2003-02-26 2010-03-04 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
CA2546486A1 (en) * 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
AU2005276132B2 (en) 2004-08-26 2011-09-29 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
EP1794156A2 (en) * 2004-09-23 2007-06-13 Pfizer Products Incorporated Trombopoietin receptor agonists
JP2008521862A (ja) * 2004-12-01 2008-06-26 デブジェン エヌブイ イオンチャンネル、特にｋｖファミリーのイオンチャンネルと相互作用する５−カルボキサミド置換チアゾール誘導体
US7601355B2 (en) * 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US7745477B2 (en) * 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US7772233B2 (en) * 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
ES2531002T3 (es) * 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2009154769A1 (en) * 2008-06-19 2009-12-23 Xcovery, Inc. Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
CA2760597C (en) * 2009-05-05 2017-08-22 F. Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
US8669254B2 (en) * 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
EP2303018B1 (en) 2015-10-14
AU2009260810A1 (en) 2009-12-23
EP3061752A1 (en) 2016-08-31
EP2303018A4 (en) 2012-06-20
US20110160209A1 (en) 2011-06-30
CA2728408C (en) 2017-12-05
JP5670325B2 (ja) 2015-02-18
US8697866B2 (en) 2014-04-15
NZ590542A (en) 2012-12-21
EP3061752B1 (en) 2018-02-21
RU2526618C2 (ru) 2014-08-27
ES2670665T3 (es) 2018-05-31
BRPI0914305A2 (pt) 2015-08-11
EP2303018A1 (en) 2011-04-06
PL2303018T3 (pl) 2016-06-30
JP2011524905A (ja) 2011-09-08
CA2728408A1 (en) 2009-12-23
KR101691640B1 (ko) 2016-12-30
US20160176900A1 (en) 2016-06-23
CN102098917B (zh) 2016-03-16
CN102098917A (zh) 2011-06-15
IL210099A (en) 2015-11-30
BRPI0914305B1 (pt) 2021-05-11
WO2009154769A1 (en) 2009-12-23
ES2551899T3 (es) 2015-11-24
RU2011139352A (ru) 2013-04-10
KR20110044974A (ko) 2011-05-03
US20140221376A1 (en) 2014-08-07
AU2009260810B2 (en) 2015-09-17
MX2010014171A (es) 2011-07-04
US9296724B2 (en) 2016-03-29
IL210099A0 (en) 2011-02-28

Similar Documents

Publication Publication Date Title
BRPI0914305B8 (pt) compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos
EP2381775A4 (en) INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
BRPI0807146B8 (pt) compostos inibidores da atividade da akt, seu uso no tratamento de câncer e artrite, bem como composição farmacêutica compreendendo os mesmos
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
BR112014008495B8 (pt) Composto inibidor da proteína quinase, composição farmacêutica compreendendo-o e uso do mesmo para a fabricação de um medicamento para o tratamento de câncer
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BRPI0613859B8 (pt) inibidores da comt, seus usos, e composição farmacêutica
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
EA201501088A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
MX340714B (es) Inhibidores de hsp90.
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: XCOVERY HOLDING COMPANY LLC (US)

Free format text: A FIM DE ATENDER A(S) ALTERACAO(OES) DE NOME REQUERIDA(S) ATRAVES DA PETICAO NO870200054923 DE 04/05/2020, E NECESSARIO:1. ESCLARECER A DIVERGENCIA QUE HA ENTRE O ENDERECO APRESENTADO NA PETICAO SUPRA E OENDERECO DA TITULAR, CONFORME PETICAO 020100118583 DE 20/12/2010;2. APRESENTAR GRU REFERENTE AO CUMPRIMENTO DA PRESENTE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: XCOVERY HOLDINGS, INC. (US)

B25G Requested change of headquarter approved

Owner name: XCOVERY HOLDINGS, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF